合成生物学 | 再谈评估模型中的商业合理性(四)

CPHI制药在线
Jun 25, 2025

关注并星标CPHI制药在线合成生物学项目是为人服务,其最终目的还是商业用途。评估模型中的商业合理性维度包括需求与孵化性、产品性能与技术壁垒两个方面。设立替代成本阈值(RCT)与政策激励效应(PM),性能溢价率(PP)与专利覆盖率(PC)4个指标。下面再做一些深度解析。一、在合成生物学项目的商业合理性评估中,替代成本阈值(RCT)与政策激励效应(PM)是判断产品能否突破市场壁垒的核心指标。RCT(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10